Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02637 海西新藥
HAIXI PHARMA
Listing Date2025/10/17    Listing Tomorrow
Listing Price86.400
Grey Market Performance
Last updated: 16/10/2025 18:48  Refresh
  • Bright Smart
    up 107.900 +21.500 (+24.884%)
    High
    168.000
     
    Low
    101.000
    Volume
    34,400
    One Lot Profit
    +1,075.00
  • Phillip
    up 108.100 +21.700 (+25.116%)
    High
    176.000
     
    Low
    105.000
    Volume
    394,000
    One Lot Profit
    +1,085.00
  • Futu
    up 107.600 +21.200 (+24.537%)
    High
    200.000
     
    Low
    106.000
    Volume
    683,900
    One Lot Profit
    +1,060.00
  • Bid
  • Ask
  • 107.900
  • (1) 50
  • 250 (4)
  • 108.000
  • 107.800
  • (2) 150
  • 0 (0)
  • 108.100
  • 107.700
  • (1) 100
  • 0 (0)
  • 108.200
  • 107.600
  • (1) 50
  • 0 (0)
  • 108.300
  • 107.500
  • (0) 0
  • 100 (2)
  • 108.400
  • 107.400
  • (0) 0
  • 100 (1)
  • 108.500
  • 107.300
  • (0) 0
  • 0 (0)
  • 108.600
  • 107.200
  • (0) 0
  • 0 (0)
  • 108.700
  • 107.100
  • (0) 0
  • 50 (1)
  • 108.800
  • 107.000
  • (1) 100
  • 0 (0)
  • 108.900
  • Bid
  • Ask
  • 108.100
  • (3) 250
  • 100 (2)
  • 108.300
  •  
  • (7) 2.1K
  • 0 (0)
  •  
  •  
  • (1) 50
  • 0 (0)
  •  
  •  
  • (1) 1.3K
  • 0 (0)
  •  
  •  
  • (2) 550
  • 0 (0)
  •  
 
Hide
COMPANY PROFILE

Fujian Haixi Pharmaceuticals Co. Ltd. is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of innovative drug candidates.

--

As of September 30, 2025, the Group’s commercialized product portfolio primarily consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. According to the report, these therapeutic areas accounted for over 25% of the total pharmaceutical sales in China in 2023.

--

The Group had obtained approval from the NMPA for 15 generic drugs and established a pipeline of four innovative drug candidates as of September 30, 2025, making it a key market participant in the pharmaceutical industry in China. The flagship generic drugs in the Group’s product portfolio include Anbili, Haihuitong, Ruiantuo and Saixifu, all were selected in the national VBP schemes.

--

The Group have established a global patent portfolio that consisted of 37 patents, including 18 in overseas jurisdictions covering U.S., Canada, Australia, Japan, Korea, Singapore, India and 29 European countries. The Group generated revenue from 13 approved products. The Group’s customers mainly consist of state-owned pharmaceutical distribution companies, and pharmacies and other retailers.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot50
GLOBAL OFFERING
No. of Offer Shares11.50M H shares
No. of International Offer Shares10.35M H shares
No. of HK Offer Shares1.15M H shares
Offer Price$69.88 - $86.40
Stock Code2637
Sponsor(s)Huatai Financial Holdings (Hong Kong) Limited, CMB International Capital Limited
Underwriter(s)Huatai Financial Holdings (Hong Kong) Limited, CMB International Capital Limited, SDICS International Securities (Hong Kong) Limited, Guosen Securities (HK) Brokerage Company, Limited, Futu Securities International (Hong Kong) Limited, China Industrial Securities International Capital Limited, CMBC Securities Company Limited, Zhongtai International Securities Limited
TIME TABLE
Application PeriodOct 09 (Thu) - noon, Oct 14 (Tue)
Price Determination DateOct 15 (Wed)
Result Announcement DateOn or before Oct 16 (Thu)
Result Announcement DateOn or before Oct 16 (Thu)
Result Announcement DateOn or before Oct 17 (Fri)
Dealings in Shares commence onOct 17, 2025. (Fri)
Reallocation of Shares Offered
Sales Statistics (HKD)
Offer Price$69.88 - $86.40
Capitalization (H Shares)5.50B - 6.80B
NAV / share ($)$18.53 - $20.87 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 78.14, the net proceeds raised would be HKD 848.00M, of which
52% : Continuous investment in R&D to advance the drug candidates in pipeline and to enrich product portfolio
23% : Improve R&D capacities and pursue collaboration opportunities
8% : Enhance commercialization capabilities and expand market presence
7% : Improve and optimize R&D and manufacturing systems
10% : Working capital
IPO NEWS
16/10/2025 18:35
{New Stock}HAIXI PHARMA(02637) ends up 25.12% on grey market
16/10/2025 16:20
{New Stock}HAIXI PHARMA up 40.28% at HK$121.2 on grey market
Related Document
Prospectus Prospectus  Chinese VersionProspectus  English Version
Remark： The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
 :
Subscribing Lot :
Subscribing Fee :
Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2025 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.